A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02173249
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
A Multi-Center Study Evaluating the Safety of AC-170 0.24%
Phase 3
Completed
- Conditions
- Atopic Disease (Including Allergic Conjunctivitis)
- Interventions
- Drug: AC-170 0%
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 512
- Registration Number
- NCT02132169
- Locations
- 🇺🇸
Ora, Inc., Andover, Massachusetts, United States
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Phase 3
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: AC-170 0.24%Drug: AC-170 0%
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT01881113
- Locations
- 🇺🇸
Ora, Inc., Andover, Massachusetts, United States
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Phase 3
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: AC-170 0%Drug: AC-170 0.24%
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2017-10-10
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01685242
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
Phase 3
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: AC-170 0%Drug: AC-170 0.24%
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT01551056
- Locations
- 🇺🇸
Ora, Inc., Andover, Massachusetts, United States
A Comparison of the Safety and Comfort of AC-170
Phase 1
Completed
- Conditions
- Normal Ocular Health
- Interventions
- Drug: AC-170 0.24% (Formulation 2)Drug: AC-170 0.17%Drug: AC-170 0.24% (Formulation 1)
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01495338
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
Phase 2
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: AC-170 0.05%Drug: AC-170 0.1%Drug: AC-170 0.24%Drug: AC-170 0%
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2017-08-30
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT01332188
- Locations
- 🇺🇸
Ora, Inc., Andover, Massachusetts, United States
Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CACâ„¢ Model
Phase 2
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: AC-150 ComboDrug: AC-150B 0.005%Drug: AC-150A 0.1%Drug: Vehicle
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT01134328
- Locations
- 🇺🇸
Ora, Inc, Andover, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath